Alnylam Pharmaceuticals
ALNY
#824
Rank
$21.38 B
Marketcap
$170.37
Share price
-1.45%
Change (1 day)
-24.68%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio as of December 2023 (TTM): 12.4

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.4043. At the end of 2023 the company had a P/S ratio of 12.8.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2023

PS ratio at the end of each year

Year P/S ratio Change
202312.8-54.43%
202228.217.32%
202124.0-21.59%
202030.6-47.89%
201958.8-40.29%
201898.5-29.73%
2017140105.69%
201668.1-65.05%
201519531.6%
201414870.45%
201386.9505.26%
201214.4241.19%
20114.210.83%
20104.17-43.09%
20097.33-31.15%
200810.7-54.28%
200723.3-20.88%
200629.4-34.68%
200545.133.85%
200433.7

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
3.81-69.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
2.37-80.93%๐Ÿ‡ซ๐Ÿ‡ท France
6.83-44.95%๐Ÿ‡บ๐Ÿ‡ธ USA
7.46-39.84%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
1.42-88.57%๐Ÿ‡บ๐Ÿ‡ธ USA
0.7384-94.05%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
10.5-15.71%๐Ÿ‡บ๐Ÿ‡ธ USA